M
Marco Stellato
Researcher at Università Campus Bio-Medico
Publications - 50
Citations - 467
Marco Stellato is an academic researcher from Università Campus Bio-Medico. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 8, co-authored 29 publications receiving 199 citations. Previous affiliations of Marco Stellato include University of Milan.
Papers
More filters
Journal ArticleDOI
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.
Emanuela Dell'Aquila,Chiara Cremolini,Tea Zeppola,Sara Lonardi,Francesca Bergamo,Gianluca Masi,Marco Stellato,Federica Marmorino,Marta Schirripa,Federica Urbano,Monica Ronzoni,Gianluca Tomasello,A. Zaniboni,Patrizia Racca,Angela Buonadonna,Giacomo Allegrini,E. Fea,S. Di Donato,Silvana Chiara,G. Tonini,Daniela Tomcikova,Luigi Boni,Alfredo Falcone,Daniele Santini +23 more
TL;DR: The prognostic role of NLR was confirmed in mCRC pts treated with bevacizumab plus chemotherapy in the first line, showing the worse prognosis of pts with high NLR, and the advantage of the triplet is independent ofNLR at baseline.
Journal ArticleDOI
Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer.
Alessandra Raimondi,Pierangela Sepe,Emma Zattarin,Alessia Mennitto,Marco Stellato,Melanie Claps,Valentina Guadalupi,Elena Verzoni,Filippo de Braud,Giuseppe Procopio +9 more
TL;DR: Several promising biomarkers of response to immunotherapy with ICIs have been identified, though without conclusive results upon their potential predictive value in mRCC, and these could provide useful tools to be applied in the everyday clinical practice.
Journal ArticleDOI
Prognostic and predictive factors in pancreatic cancer.
Emanuela Dell'Aquila,Claudia Angela Maria Fulgenzi,Alessandro Minelli,Fabrizio Citarella,Marco Stellato,Francesco Pantano,Marco Russano,Maria Concetta Cursano,Andrea Napolitano,Tea Zeppola,Bruno Vincenzi,Giuseppe Tonini,Daniele Santini +12 more
TL;DR: The aim of this review is to provide an overview of prognostic and predictive markers used in clinical practice and to explore the most promising fields of research in terms of treatment selection and tailored therapy in pancreatic cancer.
Journal ArticleDOI
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)
Sara Elena Rebuzzi,Alessio Signori,Giuseppe Luigi Banna,Marco Maruzzo,Ugo De Giorgi,Paolo Pedrazzoli,Andrea Sbrana,Paolo Andrea Zucali,Cristina Masini,Emanuele Naglieri,Giuseppe Procopio,Sara Merler,Laura Tomasello,Lucia Fratino,Cinzia Baldessari,Riccardo Ricotta,Stefano Panni,Veronica Mollica,Mariella Sorarù,Matteo Santoni,Alessio Cortellini,Veronica Prati,Hector Soto Parra,Marco Stellato,Francesco Atzori,Sandro Pignata,Carlo Messina,Marco Messina,Franco Morelli,Giuseppe Prati,Franco Nolè,Francesca Vignani,Alessia Cavo,Giandomenico Roviello,Francesco Pierantoni,Chiara Casadei,Melissa Bersanelli,Silvia Chiellino,Federico Paolieri,Matteo Perrino,Matteo Brunelli,Roberto Iacovelli,Camillo Porta,Sebastiano Buti,Giuseppe Fornarini +44 more
TL;DR: The Meet-URO score allowed for the accurate stratification of pretreated mRCC patients receiving nivolumab and is easily applicable for clinical practice at no additional cost.
Journal ArticleDOI
Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes.
Melanie Claps,Alessia Mennitto,Valentina Guadalupi,Pierangela Sepe,Marco Stellato,Emma Zattarin,Sommer Silke Gillessen,Cora N. Sternberg,Alfredo Berruti,Filippo de Braud,Elena Verzoni,Giuseppe Procopio +11 more
TL;DR: The present review summarizes the results obtained treating advanced prostate cancer patients with immune-checkpoints inhibitors and analyzes potential mechanisms of both resistance and sensitivity, in order to hypothesize possible avenues of special interest for future research.